Diabetes

Pharmacists have positive impacts on health outcomes for diabetes and patients using CGM devices, including reductions in A1c.

Hypertension and obstructive sleep apnea are considered independent risk factors for cardiovascular diseases as well as diabetes.

Further studies are needed to further confirm the association between glucagon-like peptide 1 medication and reductions in dementia risk.

Type 1 diabetes can cause long-term complications, including the development of autoimmune diseases.

Clinical pharmacists counsel patients during the intervention and make informed medication changes based on the data received from continuous glucose monitoring (CGM).

As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.

All 3 types of virtual diabetes self-management interventions lead to better results in hemoglobin A1c over a 6-month period.

The integration of CGM into pharmacy practice represents a significant opportunity for pharmacists to provide enhanced patient care.

The outpatient endoscopic procedure modifies duodenal dysfunction and restores metabolic health.

Heather Johnson, PharmD, BCACP, CTTS, and Heather Roth, BSPharm, RPh, discuss medications and devices used for improving cardiovascular health among patients with or without diabetes.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses the various errors patients experience when using CGM devices.

Heather Johnson, PharmD, BCACP, CTTS, and Heather Roth, BSPharm, RPh, compare patients’ diabetes outcomes in clinical and community pharmacy settings.

Control-IQ+ was associated with a greater reduction in glycated hemoglobin compared to a continuous glucose monitor alone.

A recent study found that continuous glucose monitors could help improve patient comfort, reduce resource use, and improve outcomes.

Tirzepatide and semaglutide show long-term health care cost savings but, the high cost of the medications offset the savings.

Among various weights and diabetes diagnoses, researchers explored the differences in patients’ food perceptions when considering weight management and appetite.

These findings challenge the common assumption that older adults might struggle to use more advance medical devices.

Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol levels could potentially be a valuable biomarker for determining the risk of diabetic kidney disease.

In a previous study, results showed that patients taking semaglutide could be at a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION), causing blindness.

The feasibility study shows that the STEADY intervention is possible for patients with type 1 diabetes and eating disorders without deteriorating glycemic control.

However, investigators did not determine the association between compatibility status and loss-of-signal alarms.

A new study found that GLP-1s were not associated with an increased risk of suicidal ideation, self-harm, or suicide compared to DPP-4 and SGLT-2 inhibitors.

Authors of a research letter published in JAMA said that the decrease in glycemic control may be due to consequences of the COVID-19 pandemic, such as sedentary behavior and increased mental health stressors.

The increased risk of symptoms only includes respiratory-related symptoms or brain fog.

The technology will be available to patients in the United States in March 2025.

Semaglutide has been in shortage since 2022 due to increased demand.

Tirzepatide (Mounjaro, Zepbound), a glucagon-like peptide-1 (GLP-1) medication, demonstrates improved diabetes control and decreases in insulin requirements.

A recent metanalysis found that patients with type 1 diabetes had a 50% higher chance of developing dementia.

By 12 weeks, investigators report that SkinTE facilitated significantly more wound closures compared with the standard of care.

Among a diverse cohort of patients with type 2 diabetes (T2D), researchers examined the use of automated insulin delivery for lowering hemoglobin A1c levels.